A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

NCT ID: NCT02194699

Last Updated: 2018-05-15

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

856 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-30

Study Completion Date

2017-09-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting β2-agonist and having a history of asthma exacerbations. Approximately 770 subjects will be randomized globally. Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uncontrolled Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tralokinumab

Tralokinumab subcutaneous injection

Group Type EXPERIMENTAL

Experimental: Tralokinumab

Intervention Type BIOLOGICAL

Tralokinumab subcutaneous injection

Placebo

Placebo subcutaneous injection

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo subcutaneous injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: Tralokinumab

Tralokinumab subcutaneous injection

Intervention Type BIOLOGICAL

Placebo

Placebo subcutaneous injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 12 -75
2. Documented physician-diagnosed asthma.
3. Documented treatment with ICS at a total daily dose corresponding to ≥500μg fluticasone propionate dry powder formulation equivalents) and a LABA
4. Morning pre-BD FEV1 value of ≥40 and \<80% value (\<90% for patients 12 to 17 years of age) of their PNV.
5. Post-BD reversibility of ≥12% and ≥200 mL in FEV1
6. ACQ-6 score ≥1.5

Exclusion Criteria

1. Pulmonary disease other than asthma
2. History of anaphylaxis following any biologic therapy
3. Hepatitis B, C or HIV
4. Pregnant or breastfeeding
5. History of cancer
6. Current tobacco smoking or a history of tobacco smoking for ≥ 10 pack-years
7. Previous receipt of tralokinumab
Minimum Eligible Age

12 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher Brightling, MD

Role: PRINCIPAL_INVESTIGATOR

Institute for Lung Health, United Kingdom

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Hoover, Alabama, United States

Site Status

Research Site

Huntsville, Alabama, United States

Site Status

Research Site

Scottsdale, Arizona, United States

Site Status

Research Site

Little Rock, Arkansas, United States

Site Status

Research Site

Bakersfield, California, United States

Site Status

Research Site

Buena Park, California, United States

Site Status

Research Site

Encinitas, California, United States

Site Status

Research Site

Lakewood, California, United States

Site Status

Research Site

Lomita, California, United States

Site Status

Research Site

Northridge, California, United States

Site Status

Research Site

Palmdale, California, United States

Site Status

Research Site

Roseville, California, United States

Site Status

Research Site

Sacramento, California, United States

Site Status

Research Site

San Francisco, California, United States

Site Status

Research Site

Thousand Oaks, California, United States

Site Status

Research Site

Ventura, California, United States

Site Status

Research Site

Walnut Creek, California, United States

Site Status

Research Site

Centennial, Colorado, United States

Site Status

Research Site

Celebration, Florida, United States

Site Status

Research Site

DeLand, Florida, United States

Site Status

Research Site

Gainesville, Florida, United States

Site Status

Research Site

Hialeah, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

New Port Richey, Florida, United States

Site Status

Research Site

Orlando, Florida, United States

Site Status

Research Site

Palmetto Bay, Florida, United States

Site Status

Research Site

Port Charlotte, Florida, United States

Site Status

Research Site

St. Petersburg, Florida, United States

Site Status

Research Site

Tampa, Florida, United States

Site Status

Research Site

Winter Park, Florida, United States

Site Status

Research Site

Columbus, Georgia, United States

Site Status

Research Site

Gainesville, Georgia, United States

Site Status

Research Site

Savannah, Georgia, United States

Site Status

Research Site

Eagle, Idaho, United States

Site Status

Research Site

Evergreen Park, Illinois, United States

Site Status

Research Site

Kenilworth, Illinois, United States

Site Status

Research Site

Peoria, Illinois, United States

Site Status

Research Site

White Marsh, Maryland, United States

Site Status

Research Site

Fall River, Massachusetts, United States

Site Status

Research Site

Reno, Nevada, United States

Site Status

Research Site

Northfield, New Jersey, United States

Site Status

Research Site

Ocean City, New Jersey, United States

Site Status

Research Site

Teaneck, New Jersey, United States

Site Status

Research Site

Toms River, New Jersey, United States

Site Status

Research Site

Verona, New Jersey, United States

Site Status

Research Site

Albuquerque, New Mexico, United States

Site Status

Research Site

Larchmont, New York, United States

Site Status

Research Site

The Bronx, New York, United States

Site Status

Research Site

The Bronx, New York, United States

Site Status

Research Site

Wappingers Falls, New York, United States

Site Status

Research Site

Burlington, North Carolina, United States

Site Status

Research Site

Charlotte, North Carolina, United States

Site Status

Research Site

Greensboro, North Carolina, United States

Site Status

Research Site

Canton, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Tulsa, Oklahoma, United States

Site Status

Research Site

Tulsa, Oklahoma, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Rock Hill, South Carolina, United States

Site Status

Research Site

Arlington, Texas, United States

Site Status

Research Site

Baytown, Texas, United States

Site Status

Research Site

Frisco, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

Kingwood, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Orem, Utah, United States

Site Status

Research Site

Salt Lake City, Utah, United States

Site Status

Research Site

Fairfax, Virginia, United States

Site Status

Research Site

Greenfield, Wisconsin, United States

Site Status

Research Site

Madison, Wisconsin, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Sherwood Park, Alberta, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Ajax, Ontario, Canada

Site Status

Research Site

Ajax, Ontario, Canada

Site Status

Research Site

Burlington, Ontario, Canada

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Mississauga, Ontario, Canada

Site Status

Research Site

Ottawa, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Windsor, Ontario, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Saint-Charles-Borromée, Quebec, Canada

Site Status

Research Site

Saskatoon, Saskatchewan, Canada

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Talcahuano, , Chile

Site Status

Research Site

Brandýs nad Labem, , Czechia

Site Status

Research Site

Jindřichův Hradec, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Praha 10 - Strasnice, , Czechia

Site Status

Research Site

Rokycany, , Czechia

Site Status

Research Site

Teplice, , Czechia

Site Status

Research Site

Catania, , Italy

Site Status

Research Site

Genova, , Italy

Site Status

Research Site

Legnago, , Italy

Site Status

Research Site

Messina, , Italy

Site Status

Research Site

Milan, , Italy

Site Status

Research Site

Napoli, , Italy

Site Status

Research Site

Palermo, , Italy

Site Status

Research Site

Pisa, , Italy

Site Status

Research Site

Salerno, , Italy

Site Status

Research Site

Verona, , Italy

Site Status

Research Site

Asahi-shi, , Japan

Site Status

Research Site

Chūōku, , Japan

Site Status

Research Site

Fukui-shi, , Japan

Site Status

Research Site

Fukushima, , Japan

Site Status

Research Site

Habikino-shi, , Japan

Site Status

Research Site

Himeji-shi, , Japan

Site Status

Research Site

Hiroshima, , Japan

Site Status

Research Site

Itabashi-ku, , Japan

Site Status

Research Site

Izumo-shi, , Japan

Site Status

Research Site

Kagoshima, , Japan

Site Status

Research Site

Kanazawa, , Japan

Site Status

Research Site

Kanuma-shi, , Japan

Site Status

Research Site

Kasuga-shi, , Japan

Site Status

Research Site

Kishiwada-shi, , Japan

Site Status

Research Site

Kobe, , Japan

Site Status

Research Site

Kobe, , Japan

Site Status

Research Site

Kochi, , Japan

Site Status

Research Site

Maebashi, , Japan

Site Status

Research Site

Matsue, , Japan

Site Status

Research Site

Matsusaka-shi, , Japan

Site Status

Research Site

Meguro-ku, , Japan

Site Status

Research Site

Minatoku, , Japan

Site Status

Research Site

Morioka, , Japan

Site Status

Research Site

Nagasaki, , Japan

Site Status

Research Site

Nagoya, , Japan

Site Status

Research Site

Nishinomiya-shi, , Japan

Site Status

Research Site

Sagamihara-shi, , Japan

Site Status

Research Site

Sakaide-shi, , Japan

Site Status

Research Site

Sapporo, , Japan

Site Status

Research Site

Sasebo-shi, , Japan

Site Status

Research Site

Seto-shi, , Japan

Site Status

Research Site

Shibuya-ku, , Japan

Site Status

Research Site

Shinagawa-ku, , Japan

Site Status

Research Site

Shinjuku-ku, , Japan

Site Status

Research Site

Sumida-ku, , Japan

Site Status

Research Site

Takamatsu, , Japan

Site Status

Research Site

Toshima-ku, , Japan

Site Status

Research Site

Touon-shi, , Japan

Site Status

Research Site

Toyama, , Japan

Site Status

Research Site

Tsu, , Japan

Site Status

Research Site

Tsukubo-gun, , Japan

Site Status

Research Site

Uozu-shi, , Japan

Site Status

Research Site

Yokohama, , Japan

Site Status

Research Site

Yokohama, , Japan

Site Status

Research Site

Yokohama, , Japan

Site Status

Research Site

Yokohama, , Japan

Site Status

Research Site

Yokohama, , Japan

Site Status

Research Site

Guadalajara, , Mexico

Site Status

Research Site

México, , Mexico

Site Status

Research Site

Monterrey, , Mexico

Site Status

Research Site

Monterrey, , Mexico

Site Status

Research Site

Villahermosa, , Mexico

Site Status

Research Site

Caloocan City, , Philippines

Site Status

Research Site

Iloilo City, , Philippines

Site Status

Research Site

Lipa City, , Philippines

Site Status

Research Site

Pasig, , Philippines

Site Status

Research Site

Quezon City, , Philippines

Site Status

Research Site

Quezon City, , Philippines

Site Status

Research Site

San Fernando City, , Philippines

Site Status

Research Site

Chelyabinsk, , Russia

Site Status

Research Site

Izhevsk, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Novosibirsk, , Russia

Site Status

Research Site

Novosibirsk, , Russia

Site Status

Research Site

Novosibirsk, , Russia

Site Status

Research Site

Omsk, , Russia

Site Status

Research Site

Perm, , Russia

Site Status

Research Site

Petrozavodsk, , Russia

Site Status

Research Site

Pyatigorsk, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Saratov, , Russia

Site Status

Research Site

Ulyanovsk, , Russia

Site Status

Research Site

Vladikavkaz, , Russia

Site Status

Research Site

Volgograd, , Russia

Site Status

Research Site

Yaroslavl, , Russia

Site Status

Research Site

Yekaterinburg, , Russia

Site Status

Research Site

Boksburg North, , South Africa

Site Status

Research Site

Durban, , South Africa

Site Status

Research Site

KwaDukuza, , South Africa

Site Status

Research Site

Mount Edgecombe, , South Africa

Site Status

Research Site

Mowbray, , South Africa

Site Status

Research Site

Port Elizabeth, , South Africa

Site Status

Research Site

Kaohsiung Hsien, , Taiwan

Site Status

Research Site

Keelung, , Taiwan

Site Status

Research Site

New Taipei City, , Taiwan

Site Status

Research Site

Cherkasy, , Ukraine

Site Status

Research Site

Dnipropetrovsk, , Ukraine

Site Status

Research Site

Ivano-Frankivsk, , Ukraine

Site Status

Research Site

Kharkiv, , Ukraine

Site Status

Research Site

Kharkiv, , Ukraine

Site Status

Research Site

Kremenchuk, , Ukraine

Site Status

Research Site

Kyiv, , Ukraine

Site Status

Research Site

Kyiv, , Ukraine

Site Status

Research Site

Kyiv, , Ukraine

Site Status

Research Site

Lviv, , Ukraine

Site Status

Research Site

Odesa, , Ukraine

Site Status

Research Site

Sumy, , Ukraine

Site Status

Research Site

Sumy, , Ukraine

Site Status

Research Site

Uzhhorod, , Ukraine

Site Status

Research Site

Zaporizhzhya, , Ukraine

Site Status

Research Site

Zaporizhzhya, , Ukraine

Site Status

Research Site

Bradford, , United Kingdom

Site Status

Research Site

Cambridge, , United Kingdom

Site Status

Research Site

Chertsey, , United Kingdom

Site Status

Research Site

Glasgow, , United Kingdom

Site Status

Research Site

Leicester, , United Kingdom

Site Status

Research Site

Liverpool, , United Kingdom

Site Status

Research Site

Manchester, , United Kingdom

Site Status

Research Site

Northwood, , United Kingdom

Site Status

Research Site

Sidcup, , United Kingdom

Site Status

Research Site

Wishaw, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Chile Czechia Italy Japan Mexico Philippines Russia South Africa Taiwan Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Gottlow M, Svensson DJ, Lipkovich I, Huhn M, Bowen K, Wessman P, Colice G. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. BMC Pulm Med. 2019 Jul 17;19(1):129. doi: 10.1186/s12890-019-0889-4.

Reference Type DERIVED
PMID: 31315668 (View on PubMed)

Carlsson M, Braddock M, Li Y, Wang J, Xu W, White N, Megally A, Hunter G, Colice G. Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. Drug Saf. 2019 Jun;42(6):769-784. doi: 10.1007/s40264-018-00788-w.

Reference Type DERIVED
PMID: 30649752 (View on PubMed)

Panettieri RA Jr, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, Colice G, Brightling CE. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018 Jul;6(7):511-525. doi: 10.1016/S2213-2600(18)30184-X. Epub 2018 May 20.

Reference Type DERIVED
PMID: 29792288 (View on PubMed)

Panettieri RA Jr, Wang M, Braddock M, Bowen K, Colice G. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018 Mar 1;10(6):473-490. doi: 10.2217/imt-2017-0191. Epub 2018 Mar 14.

Reference Type DERIVED
PMID: 29536781 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D2210C00008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TNF-alpha Directed Therapy in Asthma
NCT00278083 COMPLETED PHASE2